Differentiated Therapeutics (dx/tx) has built the first end-to-end discovery engine for Targeted Protein Degradation (TPD) which drives the discovery and optimization of novel protein degraders designed to eliminate the genetically defined drivers of disease. Due to the highly heterogeneous nature of pharmaceutical development, our field has yet to experience an organization built from the ground up with an end-to-end platform that deploys a custom toolkit of applications for specific problems in the drug development process. Dx/tx fills this gap. We believe our organization can only be successful by discovering differentiated therapeutic development strategies for which our platform drives significant value.
The vast complexity of biological signaling requires protein-protein interactions to impart post-translational modifications and molecules that induce proximity gave us paradigm-shifting medicines like rapamycin, lenalidomide, and pomalidomide. Yet, 95% of nature’s E3-substrate chemical space remains unmapped for its enormous potential - until now. At Differentiated Therapeutics, we’re combining breakthroughs in biophysics, chemoproteomics, molecular simulation, artificial intelligence (AI), and automation to map the conformational basis of induced proximity and to use that map to design novel degrader therapeutics.
Total Funding: $5M
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2021
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Differentiated Therapeutics
Bryce Allen
Co-founder & CEO
Diala Ezzeddine
Co-Founder & COO